Quoin Pharmaceuticals, LTD 10-Q quarterly reports

Quoin Pharmaceuticals reports a significant increase in R&D expenses for Q1 2026, alongside continued net losses and substantial doubt about its ability to continue as a going concern.

Quoin Pharmaceuticals reports increased Q3 2025 net losses and cash burn, but secures $19.9 million in new capital and gains FDA Orphan Drug Designation for QRX003.

Quoin Pharmaceuticals Ltd. reported a significant increase in net loss for Q2 2025, driven by a substantial rise in research and development expenses, raising substantial doubt about its ability to continue as a going concern.

Quoin Pharmaceuticals reports increased R&D spending and a net loss for Q1 2025, while expressing substantial doubt about its ability to continue as a going concern.

Quoin Pharmaceuticals reported a net loss of $2.35 million for the third quarter of 2024, while continuing to advance its clinical programs for rare skin diseases.

Quoin Pharmaceuticals reported a net loss of $1.97 million for the second quarter of 2024, while advancing clinical trials for its lead product, QRX003.

Quoin Pharmaceuticals reported a net loss of $2.3 million for the first quarter of 2024, while advancing clinical trials for its lead product, QRX003.